U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H11ClF3N5O3
Molecular Weight 425.749
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DORAVIRINE

SMILES

CN1C(=O)NN=C1CN2C=CC(=C(OC3=CC(Cl)=CC(=C3)C#N)C2=O)C(F)(F)F

InChI

InChIKey=ZIAOVIPSKUPPQW-UHFFFAOYSA-N
InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)

HIDE SMILES / InChI

Description

Doravirine (MK-1439) is a nonnucleoside inhibitor of HIV reverse transcriptase (NNRTI). It displays excellent activities against not only WT viruses but also a broader panel of NNRTI-resistant viruses. Doravirine is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults who have never taken HIV medicines before. Doravirine is always used in combination with other HIV medicines.

Originator

Approval Year

2018
436
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 12.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
PIFELTRO

Approved Use

PIFELTRO, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history. (1)

Launch Date

2018
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.962 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DORAVIRINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
16.1 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DORAVIRINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DORAVIRINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
24%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DORAVIRINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://pubmed.ncbi.nlm.nih.gov/29592840/
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Population Size: 383
Sources:
https://pubmed.ncbi.nlm.nih.gov/29592840/
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/29592840/
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
Other AEs: Abnormal dreams, Nausea...
Other AEs:
Abnormal dreams (all grades, 1%)
Nausea (all grades, 7%)
Headache (all grades, 6%)
Fatigue (all grades, 6%)
Diarrhea (all grades, 5%)
Abdominal pain (all grades, 5%)
Dizziness (all grades, 3%)
Rash (all grades, 2%)
Insomnia (all grades, 1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
Other AEs: Bilirubin total increased, Creatinine increased...
Other AEs:
Bilirubin total increased (5%)
Creatinine increased (2%)
Aspartate aminotransferase increase (4%)
Lipase increased (7%)
Creatine kinase increased (5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
AEs

AEs

AESignificanceDosePopulation
Rash 2 patients
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://pubmed.ncbi.nlm.nih.gov/29592840/
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Population Size: 383
Sources:
https://pubmed.ncbi.nlm.nih.gov/29592840/
Abnormal dreams all grades, 1%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
Insomnia all grades, 1%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
Rash all grades, 2%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
Dizziness all grades, 3%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
Abdominal pain all grades, 5%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
Diarrhea all grades, 5%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
Fatigue all grades, 6%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
Headache all grades, 6%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
Nausea all grades, 7%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 3
Creatinine increased 2%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
Aspartate aminotransferase increase 4%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
Bilirubin total increased 5%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
Creatine kinase increased 5%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
Lipase increased 7%
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
NRTIs
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
unhealthy, adult
n = 383
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 383
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
Page: 5
Sourcing

Sourcing

Vendor/AggregatorIDURL
AA Blocks
AA009CJK
https://www.aablocks.com/goods/Goods/detail?id=AA009CJK
Acadechem
ACDS-0781673
http://acadechemical.com/product/229219
Adooq BioScience
A12443
https://www.adooq.com/mk-1439.html
Alichem
29200191
http://www.alichem.com/en/products/1338225-97-0.html
Allbio Pharm Co., Ltd
AF16798
http://www.allbiopharm.com/product/n/AF16798
Alsachim
4668
http://www.alsachim.com/product-C6016-glo.bal-view.html
Angel Pharmatech
AG-11429
http://www.angelpharmatech.com/1338225-97-0.html
Ark Pharma Scientific Limited
A-1852
http://www.arkpharmtech.com/product/274044.html
Ark Pharma Scientific Limited
A-1382
http://www.arkpharmtech.com/product/33333.html
BOC Sciences
1338225-97-0
https://www.bocsci.com/doravirine-cas-1338225-97-0-item-475314.html
BioChemPartner
BCP02296
http://www.biochempartner.com/1338225-97-0-BCP02296
Chem Scene
CS-5924
http://www.chemscene.com/1338225-97-0.html
Chemspace
CSSB00025757702
https://chem-space.com/CSSB00025757702
DC Chemicals
DC9308
http://www.dcchemicals.com/product_show-Doravirine_MK_1439_.html
Debye Scientific
DB-091410
http://www.debyesci.com/cas_1338225-97-0.html
Excenen
EX-A1968
https://www.excenen.com/searchresultlist.php?id=1338225-97-0
Hefei Hirisun Pharmatech Co., Ltd
HR141299
http://hirisunpharm.com/1338225-97-0.html
Lab Network
LN01344091
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01344091
MedChem Express
HY-16767
https://www.medchemexpress.com/Doravirine.html
Smolecule
S526526
http://www.smolecule.com/products/s526526
Sun-shine Chemical
Doravirine
http://www.sun-shinechem.com/Details/Doravirine/2009/1338225-97-0.html
Synblock Inc
SB17104
http://www.synblock.com/product/1338225-97-0.html
THE BioTek
bt-266308
https://www.thebiotek.com/product/inhibitors/bt-266308
abcr GmbH
AB512636
http://www.abcr.com/shop/en/AB512636
eNovation Chemicals
D570915
https://www.enovationchem.com/ProductDetails.asp?ProductID=D570915
eNovation Chemicals
Y0975591
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0975591
PubMed

PubMed

TitleDatePubMed
In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
2014
Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
2014 Feb 1
Patents

Patents

20110245296
1

Sample Use Guides

In Vivo Use Guide
Recommended dosage: One tablet taken orally once daily with or without food in adult patients. (2.1) Dosage adjustment with rifabutin: One tablet taken twice daily (approximately 12 hours apart). (2.2) Tablets: 100 mg doravirine.
Route of Administration: Oral
In Vitro Use Guide
In the presence of 50% normal human serum (NHS), Doravirine (MK-1439) showed excellent potency in suppressing the replication of WT HIV-1 virus, with a 95% effective concentration (EC95) of 20 nM, as well as K103N, Y181C, and K103N/Y181C mutant viruses with EC95 of 43, 27, and 55 nM, respectively. MK-1439 exhibited similar antiviral activities against 10 different HIV-1 subtype viruses (a total of 93 viruses).
Name Type Language
DORAVIRINE
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
DORAVIRINE [MI]
Common Name English
DORAVIRINE [USAN]
Common Name English
3-Chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile
Systematic Name English
BENZONITRILE, 3-CHLORO-5-((1-((4,5-DIHYDRO-4-METHYL-5-OXO-1H-1,2,4-TRIAZOL-3-YL)METHYL)-1,2-DIHYDRO-2-OXO-4-(TRIFLUOROMETHYL)-3-PYRIDINYL)OXY)-
Systematic Name English
DELSTRIGO COMPONENT DORAVIRINE
Brand Name English
PIFELTRO
Brand Name English
DORAVIRINE [JAN]
Common Name English
MK-1439A
Brand Name English
Doravirine [WHO-DD]
Common Name English
DORAVIRINE COMPONENT OF DELSTRIGO
Brand Name English
MK-1439
Brand Name English
doravirine [INN]
Common Name English
DORAVIRINE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
WHO-ATC J05AG06
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
WHO-ATC J05AR24
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
Code System Code Type Description
DAILYMED
913P6LK81M
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
FDA UNII
913P6LK81M
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
EVMPD
SUB177834
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
EPA CompTox
DTXSID30158386
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
NCI_THESAURUS
C171848
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
LACTMED
Doravirine
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
DRUG BANK
DB12301
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
CAS
1338225-97-0
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
PUBCHEM
58460047
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
USAN
ZZ-166
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
WIKIPEDIA
DORAVIRINE
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
ChEMBL
CHEMBL2364608
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
INN
9797
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
DRUG CENTRAL
5295
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
MERCK INDEX
m12084
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
RXCUI
2055755
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
SMS_ID
100000163528
Created by admin on Sat Dec 16 17:56:18 GMT 2023 , Edited by admin on Sat Dec 16 17:56:18 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of DORAVIRINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966